<a href="https://laohu8.com/S/PEPG">PepGen Inc.</a> Reports Unprecedented Splicing Correction in DM1 Patients with PGN-EDODM1 in Phase 1 Trial
PepGen Inc. announced positive clinical data from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). The results showed a mean splicing correction of 53.7% following a single dose, with all patients in the cohort demonstrating improved splicing. PGN-EDODM1 was generally well-tolerated, with drug-related adverse events reported as mild or moderate. The company stated that these data build upon previously reported results from lower dose cohorts and that data from the first cohort of the FREEDOM2 multiple ascending dose (MAD) study are expected in the first quarter of 2026. A copy of the corporate presentation including these results will be made available on the PepGen investor website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250924280988) on September 24, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。